68 Ga-PSMA PET/CT staging of newly diagnosed intermediate- and high-risk prostate cancer

Jonathan Kuten*, Nicola J. Mabjeesh, Hedva Lerman, Charles Levine, Sophie Barnes, Einat Even-Sapir

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Background: 68 Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography ( 68 Ga-PSMA PET/CT) is part of the initial workup of patients with intermediate and high-risk prostate cancer provided by the Israeli national health services. Objectives: To assess the incidence of metastatic spread in consecutive patients with newly diagnosed cancer, and the potential added value of 68 Ga-PSMA PET/CT to the staging imaging algorithm. Methods: Patients with newly diagnosed intermediate- and high-risk prostate cancer were referred for initial staging by 68 Ga- PSMA PET/CT between May 2016 and April 2017. Blood prostatespecific antigen (PSA) levels, clinical history, imaging reports and histopathological reports (including Gleason scores) were obtained. Maximal standardized uptake values (SUVmax) were determined for the primary lesions detected within the prostate. Results: The study included 137 consecutive patients with intermediate- and high-risk disease who underwent 68 Ga- PSMA PET/CT staging. Of these, 75 had 68 Ga-PSMA uptake in both prostate lobes, 57 had unilateral uptake, and 5 patients had no uptake. SUVmax in the primary tumor correlated significantly with PSA levels. Thirty-five patients had increased uptake compatible with metastatic disease involving lymph nodes, bone, and viscera. Twenty-seven patients had available bone scintigraphy results: 18 (69%) of their 26 bone metastases detected by 68 Ga-PSMA PET/CT were missed on bone scintigraphy. Conclusions: 68 Ga-PSMA PET/CT shows promise as a sole wholebody imaging modality for assessing the presence of soft tissue and bone metastases in the setting of prostate cancer.

Original languageEnglish
Pages (from-to)100-104
Number of pages5
JournalIsrael Medical Association Journal
Issue number2
StatePublished - Feb 2019


  • Ga-prostatespecific membrane antigen (PSMA)
  • Positron emission tomography/CT (PET/CT)
  • Prostate cancer
  • Prostate-specific antigen (PSA)


Dive into the research topics of '68 Ga-PSMA PET/CT staging of newly diagnosed intermediate- and high-risk prostate cancer'. Together they form a unique fingerprint.

Cite this